Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only.
Physical profile: Lyophilized powder. This product is sold as a research chemical and not for human or animal consumption. For laboratory use by qualified professionals.
GLP-2 (TRZ) 20mg IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
GLP-2 (TRZ) is a research peptide widely studied for its role in metabolic and glucose-regulation pathways. It functions as a dual agonist, interacting with GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Due to this dual-receptor activity, GLP-2 (TRZ) is of significant interest in experimental research focused on insulin signaling, energy balance, and metabolic regulation.
GLP-2 (TRZ) is examined in laboratory settings for its ability to influence multiple metabolic pathways simultaneously. By activating both GLP-1 and GIP receptors, researchers investigate its effects on glucose-dependent signaling mechanisms and metabolic efficiency under controlled experimental conditions.
In preclinical and experimental models, GLP-2 (TRZ) has demonstrated notable effects on pathways related to appetite regulation, energy utilization, and body composition. These characteristics make it a valuable compound for studying obesity-related mechanisms, insulin sensitivity, and endocrine system interactions. Its dual-agonist structure differentiates it from single-receptor peptides, expanding its relevance in metabolic research.
GLP-2 (TRZ) is intended strictly for research and laboratory use only. It is not approved for human or animal consumption. Ongoing studies focus on receptor binding, molecular stability, and long-term metabolic pathway interactions.
GLP-2 (TRZ) represents an important advancement in peptide-based metabolic research. Continued investigation may provide deeper insights into dual-receptor activation and its implications for future metabolic studies.
In conclusion, GLP-2 (TRZ) is a highly relevant research peptide for investigating glucose regulation and metabolic pathways. Its dual-action receptor profile makes it a valuable tool for advanced laboratory research in metabolic science.
Common side effects may include: Nausea Diarrhea Decreased appetite Vomiting. These side effects are usually mild and decrease over time. In rare cases, more serious side effects such as allergic reactions or pancreatitis may occur. Consult your healthcare provider if you experience severe or persistent side effects.
